Non-invasive test for diagnosis bladder cancer

August 18, 2015 News BioVox

Bladder cancer is the fifth most common cancer in the western world.  MDxHealth developed a urine-based bladder cancer test for patients with hematuria (blood in urine). The test will provide physicians with a cost-effective, patient-friendly diagnostic tool to accurately detect bladder cancer and monitor recurrence.

A cohort study of 154 patients with hematuria showed that the test has a negative predictive value of 98.3%. The test is based on a combination of DNA methylation biomarkers, that were developed by MDxHealth and University Erasmus Medical Center. The latter party will receive milestone payments and royalties from MDxHealth.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts